Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]

Dr Thomas Abbott, EFPIA co-lead for PIONEER, discusses data sources and access...

Dr Thomas Abbott - Head, Real World Evidence at Astellas Pharmaceuticals

Dr Thomas Abbott, EFPIA co-lead for PIONEER, discusses data sources and access to data ( Dr Thomas Abbott - Head, Real World Evidence at Astellas Pharmaceuticals )

Dr Zsuzsanna Devecseri, EFPIA co-lead for PIONEER, discusses prostate cancer...

Dr Zsuzsanna Devecseri - Head, Global Oncology Medical, Sanofi

Dr Zsuzsanna Devecseri, EFPIA co-lead for PIONEER, discusses prostate cancer outcomes ( Dr Zsuzsanna Devecseri - Head, Global Oncology Medical, Sanofi )

Future directions in glioblastoma: the potential role of TKIs

Prof Roger Stupp, Dr Giuseppe Lombardi

Future directions in glioblastoma: the potential role of TKIs ( Prof Roger Stupp, Dr Giuseppe Lombardi )

Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus...

Prof John Marshall - Georgetown University Hospital, Washington D.C., USA

Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus 6 months ( Prof John Marshall - Georgetown University Hospital, Washington D.C., USA )

State of art in systemic management of nmCRPC

Prof Stéphane Oudard - Georges Pompidou Hospital, Paris, France

State of art in systemic management of nmCRPC ( Prof Stéphane Oudard - Georges Pompidou Hospital, Paris, France )

Advanced HCC: New systemic treatment options

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt

Advanced HCC: New systemic treatment options ( Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt )

Surgical management of pancreatic cancer

Prof Ibrahim Al-Sheneber - Saudi Cancer Foundation, Khobar, Saudi Arabia

Surgical management of pancreatic cancer ( Prof Ibrahim Al-Sheneber - Saudi Cancer Foundation, Khobar, Saudi Arabia )

First- and second-line treatments for locally advanced renal cell carcinoma

Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA

First- and second-line treatments for locally advanced renal cell carcinoma ( Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA )

Highlights from IGILUC 2019

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt

Highlights from IGILUC 2019 ( Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt )

Treating ovarian cancer patients with PARP inhibitors

Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA

Treating ovarian cancer patients with PARP inhibitors ( Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA )

PARP inhibitors and their side effects in solid tumour therapy

Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA

PARP inhibitors and their side effects in solid tumour therapy ( Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA )

Benefits and challenges of using PARP inhibitors to treat metastatic breast...

Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA

Benefits and challenges of using PARP inhibitors to treat metastatic breast cancer ( Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA )

More from ecancer